On July 20th, the FDA approved Pfizer’s Nivestym, (filgrastim-aafi,) the second biosimilar to Neupogen (filgrastim), manufactured by Amgen. The drug is approved for the same indications as the reference product, including decreasing the incidence of infection due to neutropenia. Specifically, the drug has been approved to treat side effects from cancer treatment for patients:

  • With acute myeloid leukemia receiving induction or consolidation chemotherapy
  • With cancer receiving myelosuppressive chemotherapy
  • With cancer undergoing bone marrow transplant
  • Undergoing autologous peripheral blood progenitor cell collection and therapy
  • With severe chronic neutropenia

Learn more about the approval here, and view the FDA’s product label for Nivestym (filgrastim-aafi) here